Company Name: Silco Pharmaceuticals Limited
Print Company Information
Untitled Document
Trading Code: SILCOPHL Scrip Code: 18495
Untitled Document
Figure in BDT    
Market Information: Sep 18, 2019

Last Trading Price 30.00
Last Update 1:37 PM
Change*
-0.4
-1.32%
Opening Price 30.90
Adjusted Opening Price 30.40
Yesterday's Closing Price 30.40
Closing Price -
Day's Range 29.40 - 31.00
Day's Value (mn) 16.860
52 Weeks' Moving Range 23.70 - 36.20
Day's Volume (Nos.) 560,489
Day's Trade (Nos.) 379
Market Capitalization (mn) 2,868.848
*Based on Yesterday's Closing Price and Last Trading Price.

Basic Information

Authorized Capital (mn) 1,050.00
Paid-up Capital (mn) 943.70
Face/par Value 10.0
Total No. of Outstanding Securities 94,370,000
Debut Trading Date 13 Jun, 2019
Type of Instrument Equity
Market Lot 1
Sector Pharmaceuticals & Chemicals
Untitled Document
Closing Price Graph:     Total Trade Graph:     Total Volume Graph:    

Last AGM held on:
For the year ended: Jun 30, 2018

Cash Dividend -
Bonus Issue (Stock Dividend) -
Right Issue -
Year End 30-Jun
Reserve & Surplus without OCI (mn) 1,097.380
Other Comprehensive Income (OCI) (mn) 0.0

 

Interim Financial Performance: 2019

Particulars Unaudited / Audited
Q1 Q2 Half Yearly Q3 9 Months
201903
Annual
Ending on Ending on 6 Months
201812
Ending on Ending on
201809 201812 201903
Turnover/Revenue (mn) - - - 240.88 707.7Mismatch is due
to issuer's own
actual disclosure
-
Profit from continuing operations (mn) - - - 30.49 78.65Mismatch is due
to issuer's own
actual disclosure
-
Profit for the period (mn) - - - 30.49 78.65Mismatch is due
to issuer's own
actual disclosure
-
Total Comprehensive Income for the period (mn) - - - 30.49 78.65Mismatch is due
to issuer's own
actual disclosure
-
Earnings Per Share (EPS)
Basic - - - 0.470 1.220Mismatch is due
to issuer's own
actual disclosure
-
Diluted* - - - - - -
Earnings Per Share (EPS) - continuing operations
Basic - - - 0.470 1.220Mismatch is due
to issuer's own
actual disclosure
-
Diluted* - - - 0.320 0.830Mismatch is due
to issuer's own
actual disclosure
-
Market price per share at period end - - - - - -
*As per BSEC Directive No. SEC/CMRRCD/2009-193/64, dated September 21, 2010.

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars Sep 09, 2019Sep 11, 2019Sep 12, 2019Sep 15, 2019Sep 16, 2019Sep 17, 2019
Current P/E Ratio using Basic EPS
(Continuing core operations)**
21.0220.0418.9319.819.4918.69
Current P/E ratio using Diluted EPS***
(Continuing core operation)
30.929.4627.8329.128.6427.47

 

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars Sep 09, 2019Sep 11, 2019Sep 12, 2019Sep 15, 2019Sep 16, 2019Sep 17, 2019
Current P/E Ratio using Basic EPS
(Continuing core operations)**
30.5429.1127.528.7528.327.14
Current P/E ratio using Diluted EPS***
(Continuing core operation)
------
** Usually refers to "Continuing operations".
*** Calculated using bonus-adjusted number of shares as per BSEC Directive (not as per IAS 33 or BAS 33).

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year Earnings per share(EPS) EPS - Continuing Operations NAV Per Share Profit/(Loss) and OCI
Basic Diluted
Basic Diluted
PCO* Profit for the year (mn) TCI*
Original Restated Original Restated Original Restated Diluted
2017 - - - 1.60 - - 25.41 - - 102.93 102.93 102.93
2018 - - - 1.64 - 1.12 27.05 - 18.45 105.36 105.36 105.36
PCO = Profit from Continuing Operations (mn)
TCI = Total Comprehensive Income for the year (mn)

Financial Performance... (Continued)

Year Year end Price Earnings (P/E) ratio Dividend in %* Dividend Yield in %
Earnings per share(EPS) EPS - Continuing Operations
Using Basic EPS Using
Diluted EPS
Using Basic EPS Using
Diluted EPS
Original Restated
Original Restated
2017 - - - - - - - -
2018 - - - - - - - -
*B for bonus or stock dividend, otherwise cash.
*Note: Price Earnings (P/E) Ratio has been calculated as per annual financial statements submitted by the listed securities by adopting uniform income year from July to June in compliance with the provisions of the Finance Act, 2015 and BSEC Directive No. SEC/SRMIC/2011/1240/445 dated April 27, 2016. For the first time adoption of the change in the financial year, listed companies, those year-ended on March, April, July, August, September, October and December, submitted their audited accounts by adding next few months or reducing few months and P/E has been calculated accordingly.
Details of Financial Statement
Price Sensitive Information

 

Other Information of the Company

Listing Year 2019
Market Category N
Electronic Share Y
Share Holding Percentage [as on Jun 30, 2018 (year ended)]
Sponsor/Director:
0.00
Govt:
0.00
Institute:
0.00
Foreign:
0.00
Public:
0.00
Share Holding Percentage [as on Jul 31, 2019]
Sponsor/Director:
39.12
Govt:
0.00
Institute:
15.11
Foreign:
0.03
Public:
45.74
Share Holding Percentage [as on Aug 31, 2019]
Sponsor/Director:
39.12
Govt:
0.00
Institute:
19.94
Foreign:
0.03
Public:
40.91
Remarks 1.The NAV & EPS of last Financial Statements have been calculated considering Post-IPO Number of Shares. 2. Share Holding Percentage shows based on post-IPO paid up capital of the Company as per Company's letter dated April 08, 2019.
Note: This is information for the concerned that total holdings of Sponsors/Directors of most of the listed securities have changed from the month of June, 2016 than that of earlier reporting mainly due to compliance of the regulation 2(r) of the Dhaka Stock Exchange (Listing) Regulations, 2015 which reads QUOTE Sponsor means any person or institution who subscribes to the initial capital of a company or a mutual fund or a collective investment scheme. UNQUOTE
Corporate Performance at a glance

Present Operational Status
Present Loan Status as on June 30, 2018
  Short-term loan (mn) 0.00
Long-term loan (mn) 0.00
Latest Dividend Status (%)
Latest Credit Rating Status
  Short-term
Long-term
OTC/Delisting/Relisting

 

Address of the Company

Address Registered & CorporateOffice: 41, Nurani, Bankalapara, Subid Bazar,Sylhet-3100
Contact Phone +88 0821-722241, 0821-728512
Fax
E-mail info@silcopharma.com
Web Address http://www.silcopharma.com/

Note: All dynamic information of this page are only valid for Public and Debt board.
Disclaimer: This page is now under updating process. If any anomalies are found , please inform us (phone: 88-02-9564601, 7175703-11, Ext- 259).

 




STOCK EXCHANGE BUILDING, 9/F MOTIJHEEL C/A, DHAKA BANGLADESH
Phone: 88-02-9564601, 7175703-11, FAX: +88-02-9564727
Email: dse@bol-online.com, Web: http://www.dsebd.org/